Theravance Announces Positive Phase 2 Clinical Results In The MABA Respiratory...
Medical News Today: 2 views since Tuesday, July 15, 2008 at 07:08 AM
Theravance, Inc. (NASDAQ: THRX) announced the positive results from a Phase 2 study of the lead investigational compound GSK961081 ('081) in the inhaled bifunctional muscarinic antagonist-beta2 agonist (MABA) program.

Published in: Randomized Things